Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04712097 · ClinicalTrials.gov registry record · Phase 3
A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma
A Phase 3 study of Relapsed or Refractory Follicular Lymphoma, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 3
- Development phase
- 478
- Enrollment target
- 20
- Study locations
NCT04712097 is a Phase 3 study of Relapsed or Refractory Follicular Lymphoma that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 478 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT04712097, a Phase 3 study of Relapsed or Refractory Follicular Lymphoma, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 478 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the efficacy and safety of mosunetuzumab in combination with lenalidomide (M + Len) compared to rituximab in combination with lenalidomide (R + Len) in participants with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least one line of prior systemic therapy.
Conditions Studied
Interventions
- DRUG Mosunetuzumab
- DRUG Rituximab
- DRUG Lenalidomide
- DRUG Tociluzumab
Study Locations (20)
New York
- NYU Long Island Hospital - Mineola
- NYU Langone Ambulatory Care Center - New York
- Montefiore Medical Center - Montefiore Medical Park - The Bronx
- Montefiore Medical Center - The Bronx
Indiana
- Fort Wayne Medical Oncology and Hematology, Inc - Fort Wayne
- Investigative Clinical Research of Indiana, LLC - Noblesville
Michigan
- University of Michigan Health System - Ann Arbor
- Cancer & Hematology Center of West Michigan - Grand Rapids
North Carolina
- Duke University Medical Center - Durham
- Wake Forest Univ Health Svcs - Winston-Salem
Texas
- Baylor University Medical Center - Dallas
- MD Anderson Cancer Center - Houston
California
- City of Hope Comprehensive Cancer Center - Duarte
Georgia
- Winship Cancer Institute - Atlanta
Maryland
- Johns Hopkins Uni - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 478 participants |
| Start Date | 2021-10-27 |
| Est. Completion | 2029-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04712097
The ClinicalTrials.gov registry entry for NCT04712097 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 478 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed or Refractory Follicular Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Mosunetuzumab is the first listed.
NCT04712097 reports 20 study locations spanning 13 distinct geographic areas - top geographies include New York, Indiana, Michigan.
Frequently Asked Questions
What is clinical trial NCT04712097 about?
NCT04712097 is a clinical study titled "A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma". This study will evaluate the efficacy and safety of mosunetuzumab in combination with lenalidomide (M + Len) compared to rituximab in combination with lenalidomide (R + Len) in participants with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least one line of prior system...
What is the current status of trial NCT04712097?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 478 participants. The study started on 2021-10-27. Estimated completion is 2029-12-31.
What conditions does trial NCT04712097 study?
This clinical trial studies the following conditions: Relapsed or Refractory Follicular Lymphoma.
What interventions are being tested in trial NCT04712097?
The interventions under investigation include: Mosunetuzumab (DRUG), Rituximab (DRUG), Lenalidomide (DRUG), Tociluzumab (DRUG).
Who is sponsoring clinical trial NCT04712097?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04712097 being conducted?
This trial has 20 study locations across California, Georgia, Indiana, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.